(19)
(11) EP 2 340 254 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.05.2014 Bulletin 2014/21

(45) Mention of the grant of the patent:
02.04.2014 Bulletin 2014/14

(21) Application number: 09813797.9

(22) Date of filing: 15.09.2009
(51) International Patent Classification (IPC): 
A61K 31/437(2006.01)
A61P 25/08(2006.01)
A61K 31/444(2006.01)
(86) International application number:
PCT/US2009/056988
(87) International publication number:
WO 2010/031054 (18.03.2010 Gazette 2010/11)

(54)

COMPOSITIONS AND METHODS FOR TREATING EPILEPSY

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON EPILEPSIE

COMPOSITIONS ET PROCÉDÉS POUR TRAITER L ÉPILEPSIE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 15.09.2008 US 96940 P
02.06.2009 US 183209 P

(43) Date of publication of application:
06.07.2011 Bulletin 2011/27

(73) Proprietor: Biovista, Inc.
Charlottesville, VA 22903 (US)

(72) Inventors:
  • DEFTEREOS, Spyros
    GR-15342 Athens (GR)
  • PERSIDIS, Andreas
    GR-16673 Athens (GR)

(74) Representative: Elsy, David 
Withers & Rogers LLP 4 More London Riverside
London SE1 2AU
London SE1 2AU (GB)


(56) References cited: : 
US-A1- 2003 171 270
US-A1- 2006 154 968
US-A1- 2008 108 574
US-A1- 2004 228 923
US-A1- 2007 150 024
   
  • BACHURIN S ET AL: "Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES JUN 2001,, vol. 939, 1 June 2001 (2001-06-01), pages 425-435, XP002478538,
  • DECKERS C L P ET AL: "SELECTION OF ANTIEPILEPTIC DRUG POLYTHERAPY BASED ON MECHANISMS OF ACTION: THE EVIDENCE REVIEWED", EPILEPSIA, RAVEN PRESS LTD, NEW YORK, US, vol. 41, no. 11, 1 January 2000 (2000-01-01), pages 1364-1374, XP009035157, ISSN: 0013-9580, DOI: 10.1111/J.1528-1157.2000.TB00111.X
  • MURAKI T ET AL: "Inhibition of benzodiazepine and GABA receptor binding by amino-gamma-carbolines and other amino acid pyrolysate mutagens", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER SCIENCE, NL, vol. 98, no. 1, 10 February 1984 (1984-02-10), pages 35-44, XP023749611, ISSN: 0014-2999, DOI: 10.1016/0014-2999(84)90106-7 [retrieved on 1984-02-10]
  • SARKISIAN M R: "Overview of the Current Animal models for Human Seizure and Epileptic Disorders", EPILEPSY & BEHAVIOR, vol. 2, 1 January 2001 (2001-01-01), pages 201-216,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).